AgomAb Aligns With FDA On Design Of Phase 2b NOV-ERA For Ontunisertib In Crohn's Disease

AgomAb Therapeutics NV (AGMB), a clinical-stage biopharmaceutical company, announced the study design of the Phase 2b NOV-ERA trial for Ontunisertib in the treatment of Fibrostenosing Crohn's Disease, aligned with the U.